Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15949)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 2, 2016 (publication date) through May 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Dermatology
ISSN
2218-6190
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Geraghty NJ, Watson D, Adhikary SR, Sluyter R. P2X7 receptor in skin biology and diseases. World J Dermatol 2016; 5(2): 72-83 [DOI: 10.5314/wjd.v5.i2.72] |
|---|---|
| URL: | https://www.wjgnet.com/2218-6190/full/v5/i2/72.htm |
| Number | Citing Articles |
| 1 |
Nicholas J. Geraghty, Kylie J. Mansfield, Stephen J. Fuller, Debbie Watson, Ronald Sluyter. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice. Purinergic Signalling 2017; 13(4): 405 doi: 10.1007/s11302-017-9569-0
|
| 2 |
Ronald Sluyter. Protein Reviews. Advances in Experimental Medicine and Biology 2017; 1051: 17 doi: 10.1007/5584_2017_59
|
| 3 |
Aziz Ghaderpour, Ju‐Young Jeong, Youn‐Hee Kim, Yunyun Zou, Kyung‐Sun Park, Eun‐Ji Hong, Young‐Jae Koh, Seung‐Yong Seong. Taurodeoxycholate, a GPCR19 agonist, ameliorates atopic dermatitis in Balb/c mice. European Journal of Immunology 2023; 53(5) doi: 10.1002/eji.202250048
|
| 4 |
Geoffrey Burnstock. Purinergic Signalling: Therapeutic Developments. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00661
|
| 5 |
P.A.F. Pacheco, R.M.S. Galvão, A.F.M. Faria, N.l. Von Ranke, M.S. Rangel, T.M. Ribeiro, M.l. Bello, C.R. Rodrigues, V.F. Ferreira, D.R. da Rocha, R.X. Faria. 8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 Receptor-Induced dye uptake into murine Macrophages. Bioorganic & Medicinal Chemistry 2019; 27(8): 1449 doi: 10.1016/j.bmc.2018.11.036
|
| 6 |
Jessica Gaff, Fitri Octaviana, Connie Jackaman, Peter Kamerman, John Papadimitriou, Silvia Lee, Jenjira Mountford, Patricia Price. Expression in skin biopsies supports genetic evidence linking CAMKK2, P2X7R and P2X4R with HIV-associated sensory neuropathy. Journal of NeuroVirology 2023; 29(3): 241 doi: 10.1007/s13365-023-01134-2
|
| 7 |
Geoffrey Burnstock, Gillian E. Knight. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signalling 2018; 14(1): 1 doi: 10.1007/s11302-017-9593-0
|
| 8 |
Ronald Sluyter, Kara L. Vine. N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1βRelease from Murine Macrophages. Mediators of Inflammation 2016; 2016: 1 doi: 10.1155/2016/2097219
|
| 9 |
N J Geraghty, L Belfiore, D Ly, S R Adhikary, S J Fuller, W Varikatt, M L Sanderson-Smith, V Sluyter, S I Alexander, R Sluyter, D Watson. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease. Clinical and Experimental Immunology 2017; 190(1): 79 doi: 10.1111/cei.13005
|
| 10 |
Geoffrey Burnstock. The therapeutic potential of purinergic signalling. Biochemical Pharmacology 2018; 151: 157 doi: 10.1016/j.bcp.2017.07.016
|
| 11 |
T.B.-D. McEwan, R.A. Sophocleous, P. Cuthbertson, K.J. Mansfield, M.L. Sanderson-Smith, R. Sluyter. Autocrine regulation of wound healing by ATP release and P2Y2 receptor activation. Life Sciences 2021; 283: 119850 doi: 10.1016/j.lfs.2021.119850
|
| 12 |
Ronald Sluyter, Sahil Adriouch, Stephen J. Fuller, Annette Nicke, Reece A. Sophocleous, Debbie Watson. Animal Models for the Investigation of P2X7 Receptors. International Journal of Molecular Sciences 2023; 24(9): 8225 doi: 10.3390/ijms24098225
|